Keyphrases
Glucagon-like
100%
Glucose-dependent Insulinotropic Polypeptide
100%
End-stage Renal Disease
100%
Dialysis Patients
22%
Kidney Failure
22%
Placebo
22%
Nephrology
11%
Glucagon
11%
Metabolite Concentrations
11%
Metabolic Clearance Rate
11%
Plasma Half-life
11%
Sitagliptin
11%
Plasma Concentration
11%
Synthetic Humans
11%
Intact Level
11%
Dipeptidyl peptidase-4 (DPP-4)
11%
Kidney
11%
Chronic Hemodialysis
11%
Glucose-insulin System
11%
University of Copenhagen
11%
Incretin Hormones
11%
Area under the Curve
11%
Denmark
11%
Non-diabetic
11%
Control Subjects
11%
Volume of Distribution
11%
Pharmacology, Toxicology and Pharmaceutical Science
Gastric Inhibitory Polypeptide
100%
Glucagon-Like Peptide-1
100%
Elimination
100%
End Stage Renal Disease
100%
Renal Replacement Therapy-Dependent Renal Disease
22%
Placebo
22%
Hemodialysis
11%
Salicylate Sodium
11%
Volume of Distribution
11%
Glucagon
11%
Incretin
11%
Sitagliptin
11%
Observational Study
11%
Diabetes Mellitus
11%
Dipeptidyl Peptidase IV
11%
Medicine and Dentistry
End Stage Renal Disease
100%
Glucagon Like Peptide 1
100%
Gastric Inhibitory Polypeptide
100%
Metabolite
44%
Placebo
22%
Plasma Half Life
11%
Glucagon
11%
Hemodialysis
11%
Dipeptidyl Peptidase IV
11%
Metabolic Clearance Rate
11%
Diabetes Mellitus
11%
Volume of Distribution
11%
Observational Study
11%
Sitagliptin
11%
Salicylate Sodium
11%
Incretin
11%
Nephrology
11%
Biochemistry, Genetics and Molecular Biology
Gastric Inhibitory Polypeptide
100%
Glucagon-Like Peptide-1
100%
Metabolite
44%
Observational Study
11%
Metabolic Clearance Rate
11%
Glucagon
11%
Dipeptidyl Peptidase-4
11%
Incretin
11%
Hemodialysis
11%
Blood Level
11%
Plasma Half Life
11%